Neeraj Sharma

CEO & Managing Director

With a distinguished career spanning over 30 years, Neeraj has lived and worked in key pharmaceutical markets in India, South-East Asia, Latin America, and Europe. A seasoned industry leader, he brings deep expertise in General Management and P&L leadership, having successfully guided businesses through critical phases such as market entry, rapid growth, turnarounds, and M&A integrations. His diverse experience across both highly regulated and emerging markets gives him a well-rounded and strategic perspective on the global pharmaceutical landscape.

Neeraj has been part of the Strides Group since 2021. In his most recent role, he served as CEO of Steriscience, the group’s sterile injectables business promoted in partnership with TPG, a leading private equity firm.

Previously, Neeraj spent 25 years with Ranbaxy and Sunpharma, leading businesses across the globe. In his last role he was Head of the Generics Business for Western Europe, successfully building a robust sterile injectables franchise, launching several pioneering ready-to-use products across Europe.

Outside of his professional commitments, Neeraj is an avid reader and fitness enthusiast, with a deep appreciation for the nuances of Urdu poetry.

Anurag Bhagania

Chief Financial Officer

Anurag Bhagania brings with him over 25 years of extensive experience, including the last decade serving as CFO of publicly listed companies. With a background as a Chartered Accountant and an MBA in Marketing, he is focused on enhancing stakeholder wealth through transformational growth initiatives. 
 
Anurag has hands-on experience across various manufacturing industries and a wide range of finance functions. His approach focuses on driving performance, simplifying processes, improving productivity, and fostering excellence through a people-oriented and goal-focused methodology. 
 
Prior to joining OneSource, Anurag held the position of CFO at Kirloskar Oil Engines. In the past, he has worked with large global automotive and industrial manufacturing companies like SKF, Honeywell, General Electric, and others. 
 
Anurag enjoys racquet sports such as badminton and squash and travel during his free time. 

Biju Mathew

Chief Operating Officer

Biju Mathew serves as the Chief Operating Officer at OneSource, bringing over 28 years of extensive expertise in managing quality systems and regulatory compliance for the pharmaceutical industry. A pharmacist from Bangalore University, Biju has led successful audits and inspections with global regulatory agencies, including USFDA, MHRA, ANVISA, and TGA. 

An integral part of the group, Biju joined Steriscience in November 2020 after a notable tenure at Stelis Biopharma, where he served as Head of Quality and sat on the Board of Directors. At Stelis, he was instrumental in establishing a state-of-the-art drug product and drug substance manufacturing facility, along with implementing a sustainable, robust Quality System that meets stringent global regulatory standards. Prior to his work with Stelis, Biju was Head of Quality at Wockhardt Bio Pharma, where he oversaw the commissioning, qualification, and development of Quality Systems for a large-scale drug substance microbial block, helping to secure various regulatory approvals. 

Earlier in his career, Biju spent 19 years in quality roles with Strides/Agila Specialties (injectables division) and later at Mylan as Head of Quality, where he played a pivotal role in securing multiple global regulatory approvals. 

Outside of work, Biju enjoys reading, watching movies, and engaging in various sports. 

Bernhard Thurnbauer

Chief Quality Officer

Bernhard Thurnbauer is a highly accomplished pharmaceutical executive with over 30 years of leadership experience in quality assurance, compliance, and technical operations. He has held senior positions in global biotech and pharmaceutical companies, including Moderna, Roche, Acino, and B. Braun. His expertise spans sterile injectables, biologics, CDMO operations, and regulatory compliance across USFDA, EMA, and other global health authorities.

As Chief Quality Officer at OneSource, Bernhard leads the company’s global quality strategy, ensuring the highest regulatory and operational excellence. His vision focuses on developing high-performing teams, transforming quality processes through artificial intelligence, and aligning quality with business growth.

Before joining OneSource, Bernhard was the Global Head of Audit Program Management at Moderna, overseeing a US-based team responsible for ensuring compliance with stringent global regulatory requirements. He played a pivotal role in shaping audit strategies, implementing risk-based approaches, and driving efficiency improvements.

Earlier in his career, Bernhard founded a manufacturing IT and compliance consultancy in Bangkok, leveraging his extensive industry experience to help pharmaceutical companies optimize operations. He is an active member of professional organizations such as ISPE and PDA.

Outside of work, Bernhard enjoys traveling, exploring different cultures, and spending time by the sea.

Jeffrey Wong

Chief Business Officer

Jeffrey Wong is a seasoned global commercial executive with over 30 years of experience across the biopharmaceutical industry. His expertise spans bioprocessing products and CDMO services, with a focus on mammalian, microbial, and cell and gene therapy platforms.

Jeff began his career contributing to the Human Genome Project, helping to pioneer next-generation DNA and protein sequencing technologies that have become foundational to modern biologics. He later moved into biologics manufacturing, playing key roles in regulatory filings and FDA approvals for therapies such as Viadur and Zenapax.

Over the years, Jeff has held senior commercial leadership roles at Syngene International, Fujifilm Diosynth Biotechnologies, Thermo Fisher Scientific, and Sartorius Stedim Biotech. He has led strategic partnerships, secured long-term commercial agreements, and driven consistent business growth through global deal-making and alliance development.

Known for his customer-first approach and collaborative leadership, Jeff has built and led high-performing commercial teams across geographies. He is deeply committed to mentoring emerging leaders and is committed to fostering inclusive, results-driven teams that help biopharma clients scale innovation from development through to commercialization.

Preeti Kalra

Head of Human Resources

Preeti Kalra serves as the Head of Human Resources at OneSource, bringing over two decades of experience in building and scaling people functions across the pharmaceutical, global health, and public services sectors. Her expertise spans organization design, leadership development, culture transformation, talent management, and HR digitalization, developed through working in highly matrixed team environments across high growth markets in India, Australia, UAE, UK, and the United States.

At OneSource, Preeti leads the company’s people strategy, building the HR function to support its growth as India’s first pure-play specialty pharma CDMO. Her focus is on strengthening leadership capability, embedding a high-trust performance culture, and aligning talent and organizational design with the company’s business ambitions.

Before joining OneSource, Preeti was the interim CHRO and Head of People & Organization Effectiveness at Biocon Biologics, a core member of the executive leadership team, where she built the HR function behind the company’s journey to become a global biologics leader. Earlier, she served as Country Lead for Human Resources at the Bill & Melinda Gates Foundation in India and held senior HR and talent leadership roles at Serco, Shriram Life, and Ernst & Young.

Preeti holds a Post Graduate Diploma in Business Administration (Human Resources) from Symbiosis and a Bachelor of Commerce from Delhi University.

Outside of work, Preeti enjoys exploring offbeat destinations on long road trips, is passionate about weight training and fitness, and loves spending time in nature.

Arun Kumar

Founder and Non-Executive Director

Arun Kumar is a first-generation entrepreneur and known for his ability to identify great opportunities in “difficult to operate” business domains. He founded Strides Pharma Science Limited (Strides) in 1990 and has since then led the company in building a global reputation with a differentiated business model and delivering value for its stakeholders (over $5B value creation for shareholders, including distribution of the most extensive dividend by a pharmaceutical company in India).

Besides founding Strides, Arun’s family office (setup in the early 2000s) ran a differentiated set of investments spread across several companies with a combined revenue base of over a billion dollars and an invested capital of over half a billion dollars. Arun is credited to have co-founded and built India’s largest fully integrated Animal Health Company, SeQuent Scientific Limited, in less than five years. Arun’s stake in SeQuent was divested to the Carlyle Group in May 2020.

Arun is the promoter of Solara Active Pharma Sciences, a pure-play API company, targeted to become India’s second-largest API business in less than four years. Recently, Arun’s family office has entered a strategic partnership with marquee investors to build a global biologics CDMO, specialty injectable and vaccine business with capabilities across several technology platforms. The businesses run under Arun’s leadership and ownership have presence in 100+ countries with 7000+ employees and over 25 global manufacturing facilities worldwide.

Arun is a recipient of “EY Entrepreneur Of The Year Award” in the healthcare sector in 2000, Business Today “India Best CEO Award” (in mid-sized companies category), and “The Best CEO in the Pharma & Healthcare Industry” in 2014.

Neeraj Sharma

CEO and Managing Director

With a distinguished career spanning over 30 years, Neeraj has lived and worked in key pharmaceutical markets in India, South-East Asia, Latin America, and Europe. A seasoned industry leader, he brings deep expertise in General Management and P&L leadership, having successfully guided businesses through critical phases such as market entry, rapid growth, turnarounds, and M&A integrations. His diverse experience across both highly regulated and emerging markets gives him a well-rounded and strategic perspective on the global pharmaceutical landscape.

Neeraj has been part of the Strides Group since 2021. In his most recent role, he served as CEO of Steriscience, the group’s sterile injectables business promoted in partnership with TPG, a leading private equity firm.

Previously, Neeraj spent 25 years with Ranbaxy and Sunpharma, leading businesses across the globe. In his last role he was Head of the Generics Business for Western Europe, successfully building a robust sterile injectables franchise, launching several pioneering ready-to-use products across Europe.

Outside of his professional commitments, Neeraj is an avid reader and fitness enthusiast, with a deep appreciation for the nuances of Urdu poetry.

Claudio Albrecht

Non-Executive, Independent Director

Dr. Albrecht is a pharmaceutical industry veteran with over 30 years of experience. He co-founded Albrecht, Prock & Partners and previously served as CEO of STADAAG, Actavis Group, and Ratiopharm Group. He serves as an Independent Director on the Board of Dr. Reddy’s Laboratories. He has led significant internationalization and turnaround strategies, including driving Ratiopharm’s biosimilars program and orchestrating Actavis’s $6 billion sale to Watson. Dr. Albrecht holds a PhD in law and has a deep understanding of pharmaceutical strategy and global market dynamics.

Debarati Sen

Non-Executive, Independent Director

Ms. Sen is a seasoned global business leader with a track record of driving transformative business performance. She is currently the Chief Commercial Officer at Kingfisher plc, Europe’s leading home improvement retailer. Previously, she held leadership roles at HMTX Industries, most recently serving as CEO, after having served as the Group President. She has led growth and strategic initiatives across industrial and consumer businesses, including heading the largest division in 3M’s Consumer Business Group with brands like Filtrete™, Command™, and ScotchBlue™. She previously served as CEO and Managing Director of 3M India Ltd. and is an active leader in nonprofit and academic boards, including the Center for Victims of Torture (CVT), an international humanitarian organisation and the Carlson School of Management.

Vijay Karwal

Non-Executive, Independent Director

Mr. Karwal is a Managing Director at CBC Group, Asia’s largest healthcare-dedicated asset management firm, where he is focused on capital deployment and portfolio management for the firm’s private equity and royalty & private credit investment funds. With over 25 years of global experience, he has held industry leadership roles at AffaMed Therapeutics and DaVita Inc., and senior investment banking roles with Nomura, CIMB, RBS, and ABN AMRO. He also serves as an Independent Director of Mega Lifesciences PCL and brings a wealth of expertise in healthcare investments and strategic growth initiatives.

Rashmi H. Barbhaiya

Non-Executive, Independent Director

Dr. Rashmi H. Barbhaiya is a seasoned pharmaceutical executive with a global track record of driving innovation, drug development, and building successful pharma and CRO companies. He began his career with Bristol-Myers, where he spent 21 years contributing to the discovery and development of drugs for various diseases, including AIDS, cancer, and hypertension. His background combines management and entrepreneurial acumen, honed through decades of leading high-stakes pharma initiatives.

In 2002, Dr. Barbhaiya joined Ranbaxy in India as President of R&D, where he led a 900-person team and built an R&D alliance with GSK—the first of its kind for an Indian company. He was instrumental in Ranbaxy’s collaboration with the Medicines for Malaria Venture, which resulted in a cost-effective malaria treatment. Dr. Barbhaiya later co-founded Advinus Therapeutics, an innovative venture blending drug discovery with early-stage clinical services, and established partnerships with global pharma giants such as Merck and Novartis.

Dr. Barbhaiya’s recent roles include serving on advisory boards and scientific committees for various organizations focused on neglected diseases, antimicrobial resistance, and biotech innovation. He co-founded Apinovo Pharma Innovations, a company dedicated to revitalizing U.S.-based API manufacturing. A highly regarded scientist, he holds a Ph.D. in Clinical Pharmacology from the University of London and has over 150 scientific publications.

Bharat Shah

Non-Executive Director

Bharat Shah is a seasoned professional with extensive experience in the financial services sector, encompassing banking, finance, real estate, and the securities market. He has been associated with HDFC Bank since its inception, playing a pivotal role in its formation and serving as Executive Director since December 1994. Over the years, he has contributed significantly to the bank’s growth and strategic direction.

His career reflects a strong commitment to excellence and leadership across diverse financial and industrial sectors. He holds a bachelor’s degree in Science from the University of Mumbai and a Diploma in Applied Chemistry from Borough Polytechnic, London.

Board Memberships:

Credila Financial Services Limited
Salisbury Investments Private Limited

Colin Michael Bond

Non-Executive, Independent Director

Mr. Colin is an accomplished global finance executive with 15 years of experience as the Chief Financial Officer of three publicly listed companies in Switzerland and Germany. In addition to his CFO roles, he has served full terms as a Board Member and Audit Committee Chairman for listed companies in Switzerland, the United Kingdom, and Germany.

His career is marked by a strong track record of complex and high-impact transactions, including two IPOs, a corporate spin-off, a sale to private equity, acquisitions followed by delisting, and multiple public bond issuances. Mr. Colin also has significant experience in mergers and acquisitions, corporate governance, and strategy development and execution, coupled with operational expertise in leading Audit and Risk Committees, business transformation, digitalization, IT integration, and ESG initiatives.

Mr. Colin earned his MBA from London Business School and is a Fellow of the Institute of Chartered Accountants in England and Wales (FCA). He began his professional journey with a BSc in Pharmacy from the University of Aston in Birmingham, graduating with Upper Second Class Honours in 1984, and became a Member of the Royal Pharmaceutical Society of Great Britain in 1985.